Welcome aboard, gmin! I think that CEO Joe and AE positioning into a relationship with the NSABP Foundation is a big achievement. Simply put, we can be confident they will design the study correctly. A big step up from the Phase II, when too many her2 3+ subjects were enrolled that recieve Herceptin. Kinda hard to get a significant p value when comparators get curative treatment. But in the triple negative subgroup that p value hit the mark so I think this study will stand a great chance of ultimates hitting the mark. It may take awhile to hear final results, but we will see updates on enrollment beginning, enrollment fullfilled, interim etc to create a positive news cycle.